China National Medicines Corporation Ltd. (SHA:600511)
30.32
+0.50 (1.68%)
Apr 1, 2025, 2:45 PM CST
SHA:600511 Revenue
In the year 2024, China National Medicines Corporation had annual revenue of 50.60B CNY with 1.81% growth. China National Medicines Corporation had revenue of 12.57B in the quarter ending December 31, 2024, a decrease of -4.54%.
Revenue
50.60B
Revenue Growth
+1.81%
P/S Ratio
0.45
Revenue / Employee
16.12M
Employees
3,138
Market Cap
22.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 50.60B | 901.40M | 1.81% |
Dec 31, 2023 | 49.70B | 4.20B | 9.23% |
Dec 31, 2022 | 45.50B | -970.02M | -2.09% |
Dec 31, 2021 | 46.47B | 6.09B | 15.08% |
Dec 31, 2020 | 40.38B | -4.27B | -9.56% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 26.00B |
Shenzhen Mindray Bio-Medical Electronics | 37.11B |
WuXi AppTec | 37.92B |
Aier Eye Hospital Group | 20.62B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
Yunnan Baiyao Group Co.,Ltd | 39.34B |
Shanghai United Imaging Healthcare | 10.30B |
Sichuan Biokin Pharmaceutical | 5.82B |